BioCina Pty Ltd., announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201.
BioCina, a leading pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dr. Thomas Broudy has been appointed as Chief Executive Officer to lead the company’s growth of its biologic drug substance and sterile drug product development and manufacturing services.
BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer Read More »
Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufacturing.
BioCina and NovaCina Merger Bolsters Global CDMO Industry Read More »
Exciting news from NovaCina! We’ve installed and qualified a new Cytiva SA25 GMP isolator filling line to…
BioCina Expands Perth Facility to Provide Clinical Supplies Services Read More »
Adelaide, South Australia, October 10, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22
Adelaide, South Australia, September 25, 2024/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells. EnGeneIC’s mission is to
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment Read More »
BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx Adelaide, South Australia, June 3, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx’s Recombination Based Plasmid System (RBPS) technology with BioCina’s CDMO clients. RBPS is a cutting-edge technology
ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to
Adelaide, South Australia, November 6, 2023, BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such
BioCina Expands Partnership with GPN Vaccines Read More »
ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T)
